Incidence of acute endophthalmitis after intravitreal bevacizumab injection in a tertiary hospital

Yıl 2024, , 13 - 16, 15.01.2024

Aysun Taşdemir Arı , Mustafa Berhuni , Gizem Gürbostan Soysal , Nesime Setge Tıskaoğlu

https://doi.org/10.32322/jhsm.1367325

Öz

Aims: To investigate the incidence of acute endophthalmitis after intravitreal bevacizumab injections.
Methods: Patients who received treatment with intravitreal bevacizumab (1.25 mg/0.05 ml) injections for various indications between November 2020 and March 2022 were included in this retrospective study. The patients were followed up for 4 weeks after the injection in terms of acute endophthalmitis symptoms and signs.
Results: Acute endophthalmitis developed in 1 patient after 4593 intravitreal bevacizumab injections were administered to 1427 eyes of 1026 patients, and the incidence was found to be 0.0217%. The patient who developed acute endophthalmitis underwent pars plana vitrectomy and after 3 months, a significant improvement in visual acuity was observed.
Conclusion: Development of endophthalmitis postoperatively was found to be moderately low after intravitreal bevacizumab injection. It was concluded that following asepsis rules and optimal bevacizumab preparation conditions could further reduce this.

Anahtar Kelimeler

Bevacizumab, Intravitreal injections, Endophthalmitis, Complications

Kaynakça

• Garcia J, Hurwitz HI, Sandler AB, et al. Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017.
• Rosen LS, Jacobs IA, Burkes RL. Bevacizumab in colorectal cancer: current role in treatment and the potential of biosimilars. Target Oncol. 2017;12(5):599-610.
• Ruiz-Moreno JM, Montero JA. Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome. Graefes Arch Clin Exp Ophthalmol. 2010;248(7):937-941.
• Jyothi S, Chowdhury H, Elagouz M, Sivaprasad S. Intravitreal bevacizumab (Avastin) for age-related macular degeneration: a critical analysis of literature. Eye (Lond). 2010;24(5):816-824.
• Badalà F. The treatment of branch retinal vein occlusion with bevacizumab. Curr Opin Ophthalmol. 2008;19(3):234-238.
• Seo JW, Park IW. Intravitreal bevacizumab for treatment of diabetic macular edema. Korean J Ophthalmol. 2009;23(1):17-22.
• Zayek M, Parker K, Rydzewska M, Rifai A, Bhat R, Eyal F. Bevacizumab for retinopathy of prematurity: 2-year neurodevelopmental follow-up. Am J Perinatol. 2021;38(11):1158-1166.
• Xu Y, Tan CS. Safety and complications of intravitreal injections performed in an Asian population in Singapore. Int Ophthalmol. 2017;37(2):325-332.
• Ahmed N, Rehman HU, Rafique M, Hamza MS, Mirza HA. Incidence of acute endophthalmitis after intravitreal bevacizumab injection at a tertiary care hospital in Lahore. Cureus. 2021;13(2):e13185.
• Bro T, Derebecka M, Jørstad ØK, Grzybowski A. Off-label use of bevacizumab for wet age-related macular degeneration in Europe. Graefes Arch Clin Exp Ophthalmol. 2020;258(3):503-511.
• Durand ML. Endophthalmitis. Clin Microbiol Infect. 2013;19(3):227-234.
• Li T, Sun J, Min J, et al. Safety of receiving anti-vascular endothelial growth factor intravitreal injection in office-based vs operating room settings: a meta-analysis. JAMA Ophthalmol. 2021;139(10):1080-1088.
• Artunay O, Yuzbasioglu E, Rasier R, Sengül A, Bahcecioglu H. Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection. Eye (Lond). 2009;23(12):2187-2193.
• Karimi S, Fakhri N, Ansari I, Hassanpour K, Safi S. Incidence and management of acute endophthalmitis after intravitreal injection of bevacizumab. Int Ophthalmol. 2022;42(6):1827-1833.
• Pradhan E, Duwal S, Bajimaya S, Thapa R, Sharma S, Manandhar A. Acute endophthalmitis after intravitreal bevacizumab injections at the tertiary centre in Nepal. Nepal J Ophthalmol. 2018;10(19):107-110.
• Falavarjani KG, Modarres M, Hashemi M, et al. Incidence of acute endophthalmitis after intravitreal bevacizumab injection in a single clinical center. Retina. 2013;33(5):971-974.
• Khan P, Khan L, Mondal P. Cluster endophthalmitis following multiple intravitreal bevacizumab injections from a single use vial. Indian J Ophthalmol. 2016;64(9):694-696.
• Hébert M, You E, Hammamji K, et al. Impact of patient face mask use on endophthalmitis after intravitreal anti-VEGF injections. Can J Ophthalmol. 2022;57(6):364-369.
• Bavinger JC, Yu Y, VanderBeek BL. Comparative risk of endophthalmitis after intravitreal injection with bevacizumab, aflibercept, and ranibizumab. Retina. 2019;39(10):2004-2011.
• Tanaka K, Shimada H, Mori R, et al. Safety measures for maintaining low endophthalmitis rate after intravitreal anti-vascular endothelial growth factor injection before and during the COVID-19 pandemic. J Clin Med. 2022;11(3):876.
• Sousa DC, Jalil A, Patton N, et al. Early pars plana vitrectomy in acute endophthalmitis: The Manchester Series. Ophthalmic Surg Lasers Imaging Retina. 2022;53(2):96-102.